Dr. Tiffany Pluto, D.O.
Family Medicine (Family Medicine Physician)
- Medicare participating
At a glance
- Medical school
- West Virginia School of Osteopathic Medicine (1996)
- Years since graduation
- 30
- In the NPI registry since
- 2005
- Medicare patients seen, 2024
- 204
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 1996Medical school: West Virginia School of Osteopathic Medicine
- 2005Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Family Medicine Physician primary
PA license OS010516L
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- Magee Womens Hospital of UPMC Health System Pittsburgh, PA
- Excela Health Westmoreland Regional Hospital Greensburg, PA
- Uniontown Hospital Uniontown, PA
- Excela Health - Frick Hospital Mount Pleasant, PA
- Penn Highlands Connellsville Connellsville, PA
Medical groups
- Fayette Physician Network Inc (320 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 204
- Services billed
- 947
- Patients’ average age
- 71
| Service | Times | Patients |
|---|---|---|
| Established patient office or other outpatient visit, 30-39 minutes | 396 | 188 |
| Annual wellness visit, includes a personalized prevention plan of service (pps), subsequent visit | 154 | 154 |
| Established patient office or other outpatient visit, 20-29 minutes | 116 | 86 |
| Insertion of needle into vein for collection of blood sample | 113 | 68 |
| Administration of influenza virus vaccine | 37 | 36 |
| Influenza vaccine split virus, preservative free | 20 | 20 |
| Initial preventive physical examination; face-to-face visit, services limited to new beneficiary during the first 12 months of medicare enrollment | 17 | 17 |
| Influenza vaccine, quadrivalent, preservative free, 0.5 ml dosage | 15 | 15 |
| Transitional care management services for problem of at least moderate complexity | 13 | 12 |
| Administration of pneumococcal vaccine | 11 | 11 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 1 companies reported 1 payments worth $125 in total to this clinician.
| Intuitive Surgical, Inc. | $125 |
|---|
| Food and Beverage | $125 |
|---|
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 21 industry-funded studies in 2025, from 8 companies. The companies reported $835,634 in research payments for these studies, mostly to the institutions running them.
- A phase 3 multicenter placebocontrolled randomized observerblinded trial to evaluate the efficacy safety tolerability immunogenicity and lot consistency of a 6VALENT ospabased lyme disease vaccine in healthy participa…
Pfizer Inc. - Study to Assess Safety and Efficacy of Tenapanor for Treatment of IBS-C in Pediatric Patients 12 to Less Than 18 Years
Ardelyx, Inc. · Completed · NCT05643534 - A Study of Orforglipron (LY3502970) in Participants With Type 2 Diabetes and Inadequate Glycemic Control With Insulin Glargine, With or Without Metformin and/or SGLT-2 Inhibitor
Eli Lilly Export S.a. Puerto Rico Branch · Completed · NCT06109311 - A Randomized, Placebo-controlled, Double-blind, Multicenter, 12 Week, 3-Way, Partial-replicate Crossover Pharmacodynamic Study to Assess the Equivalence of Budesonide and Albuterol (BDA) Delivered by MDI HFO Compared …
AstraZeneca Pharmaceuticals LP - A Multicentre, Parallel-group, Phase IIb, Randomised, Double blind, Placebo-controlled, 4-Arm, 24-Week Study to Evaluate the Efficacy and Safety of AZD6793 Tablets in Adult Participants with Moderate to Very Severe Ch…
AstraZeneca Pharmaceuticals LP - Long-term Extension Study to Assess Adverse Events of Oral Atogepant Tablets in Pediatric Participants (6 to 17 Years of Age) With Migraine
AbbVie Inc. · Enrolling by invitation · NCT05707949 - Study to Assess Adverse Events and Disease Activity of Oral Ubrogepant Tablets for the Acute Treatment of Migraine in Children and Adolescents (Ages 6-17)
AbbVie Inc. · Recruiting · NCT05125302 - A Randomized Double Blind Double Dummy Parallel Group Multicenter 24 to 52 Week Variable Length Study to Assess the Efficacy and Safety of Budesonide Glycopyrronium and Formoterol Fumarate Metered Dose Inhaler
AstraZeneca Pharmaceuticals LP - M23-712 - A Study of Oral Atogepant Tablets to Assess Adverse Events and Change in Disease Activity To Prevent Migraine in Participants Aged 12 to 17 Years
AbbVie Inc. - A phase third,randomised,double blind,placebo controlled,eventdriven study to evaluate the effect of baxdrostat in combination with dapagliflozin compared with dapagliflozin alone on the risk of incident heart failure…
AstraZeneca Pharmaceuticals LP
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.